Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy.

Breast Cancer · 2021 · PMC8354907 · PMID 33797023

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The time to first post-discontinuation chemotherapy showed a trend for improvement in the abemaciclib group compared with the placebo control, with median TTC 52.3 versus 26.8 months, respectively (HR: 0.651; 95% CI: 0.353–1.198) and median CFS 50.2 versus 26.8 months, respectively (HR: 0.609; 95% CI: 0.344–1.076; Online Resource 5).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.